Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT?R) modulators, which activate or inhibit LT?R signaling. LT?R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT?R complex proteins that act as LT?R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT?R, its ligands, LIGHT and LT?1?2, or its intracellular binding partners, that function to regulate LT?R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT?R signaling is provided.

Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT?R) modulators, which activate or inhibit LT?R signaling. LT?R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT?R complex proteins that act as LT?R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT?R, its ligands, LIGHT and LT?1?2, or its intracellular binding partners, that function to regulate LT?R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT?R signaling is provided.

Abstract: The invention relates to therapeutic modalities and pharmaceutical compositions for the treatment of Chlamydia-infection using cyclophilin polypeptides and its corresponding human cellular binding partner or partners as a target for intervention. The present invention relates to the use of exogenous or engrafted sources of cyclophilins, anti-cyclophilin antibodies, cyclophilin decoys, soluble forms of cyclophilin-binding partners and small molecules which are supplied extracellularly, and act presumably by interrupting the binding of cyclophilin A with its cellular binding partner(s) or receptor(s), as a treatment for Chlamydia-infection. The present invention further relates to screening assays for the identification of compounds that inhibit the interaction of cyclophilin and its Chlamydia binding partners.

Abstract: The invention relates to compositions and methods comprising lymphotoxin-beta receptor (LT&bgr;R) modulators, which activate or inhibit LT&bgr;R signaling. LT&bgr;R modulators are useful for treating lymphocyte mediated immunological diseases and cancer, and more particularly, for regulating mitochondrial-mediated apoptosis. This invention relates to soluble forms of the LT&bgr;R complex proteins that act as LT&bgr;R activating or inhibiting agents. This invention also relates to the use of soluble molecules, directed against either the LT&bgr;R, its ligands, LIGHT and LT&bgr;1&agr;2, or its intracellular binding partners, that function to regulate LT&bgr;R signaling. A novel screening method for selecting soluble receptors, antibodies and other agents that modulate LT&bgr;R signaling is provided.

Abstract: Cysteine added variants ("CAVs") of interleukin-3 are provided having one or more cysteine residues substituted for selected naturally occurring amino acid residues, or inserted into the polypeptide sequence, and preferably being further modified by deletion of certain N-terminal amino acids. Such CAVs may be additionally modified by the coupling of sulfhydryl reactive compounds to the introduced cysteine residue(s) without loss of bioactivity to produce selected homogeneously modified IL-3 and improved pharmaceutical compositions containing the same.